A Glimpse Into The Expert Outlook On TransMedics Group Through 4 Analysts
Benzinga Insights 8 months ago
Analyst Ratings
TransMedics Group (NASDAQ:TMDX) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 0 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 0 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $155.75, a high estimate of $174.00, and a low estimate of $135.00. Observing a 6.68% increase, the current average has risen from the previous average price target of $146.00.
Analyzing Analyst Ratings: A Detailed Breakdown
The perception of TransMedics Group by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mike Matson | Needham | Raises | Buy | $174.00 | $166.00 |
| William Plovanic | Canaccord Genuity | Raises | Buy | $148.00 | $147.00 |
| Mike Matson | Needham | Raises | Buy | $166.00 | $148.00 |
| Patrick Wood | Morgan Stanley | Raises | Equal-Weight | $135.00 | $123.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to TransMedics Group. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of TransMedics Group compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for TransMedics Group's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into TransMedics Group's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on TransMedics Group analyst ratings.
Unveiling the Story Behind TransMedics Group
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Financial Insights: TransMedics Group
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining TransMedics Group's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 32.24% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: TransMedics Group's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 16.91% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): TransMedics Group's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.22% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): TransMedics Group's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.65%, the company showcases efficient use of assets and strong financial health.
Debt Management: TransMedics Group's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.46, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Analyst Ratings: Simplified
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.